As of 2025-12-27, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -9.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 2,401.75 mil USD. OCUL's TTM EBITDA according to its financial statements is -246.81 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 11.3x | 8.6x |
| Forward P/E multiples | 13.6x - 15.6x | 15.0x |
| Fair Price | (14.47) - (11.83) | (12.35) |
| Upside | -215.2% - -194.2% | -198.4% |
| Date | EV/EBITDA |
| 2025-12-26 | -9.73 |
| 2025-12-24 | -9.86 |
| 2025-12-23 | -9.89 |
| 2025-12-22 | -10.08 |
| 2025-12-19 | -9.73 |
| 2025-12-18 | -10.09 |
| 2025-12-17 | -10.73 |
| 2025-12-16 | -11.31 |
| 2025-12-15 | -11.12 |
| 2025-12-12 | -11.46 |
| 2025-12-11 | -11.55 |
| 2025-12-10 | -12.19 |
| 2025-12-09 | -12.66 |
| 2025-12-08 | -12.80 |
| 2025-12-05 | -9.75 |
| 2025-12-04 | -9.62 |
| 2025-12-03 | -8.78 |
| 2025-12-02 | -8.60 |
| 2025-12-01 | -9.00 |
| 2025-11-28 | -9.38 |
| 2025-11-26 | -9.37 |
| 2025-11-25 | -9.36 |
| 2025-11-24 | -9.33 |
| 2025-11-21 | -9.46 |
| 2025-11-20 | -9.01 |
| 2025-11-19 | -9.33 |
| 2025-11-18 | -9.04 |
| 2025-11-17 | -9.15 |
| 2025-11-14 | -8.64 |
| 2025-11-13 | -8.55 |
| 2025-11-12 | -8.81 |
| 2025-11-11 | -8.57 |
| 2025-11-10 | -8.24 |
| 2025-11-07 | -8.26 |
| 2025-11-06 | -8.07 |
| 2025-11-05 | -8.22 |
| 2025-11-04 | -8.30 |
| 2025-11-03 | -8.74 |
| 2025-10-31 | -8.95 |
| 2025-10-30 | -9.09 |
| 2025-10-29 | -8.80 |
| 2025-10-28 | -8.84 |
| 2025-10-27 | -8.86 |
| 2025-10-24 | -8.81 |
| 2025-10-23 | -8.76 |
| 2025-10-22 | -8.68 |
| 2025-10-21 | -9.05 |
| 2025-10-20 | -9.40 |
| 2025-10-17 | -9.11 |
| 2025-10-16 | -9.42 |